TB-500: The Complete 2026 Guide (Mechanism, Dosing, Cost)

TB-500 at a glance:

• Drug class: Research peptide (not FDA-approved)
• Route: subcutaneous injection (in research)
• Typical frequency: weekly loading then maintenance protocols are described in non-clinical literature
• Half-life: approximately 2-3 hours after subcutaneous administration in animal studies

Most people land on a TB-500 page because they're weighing it against another option, trying to manage side effects, or trying to figure out if it's worth the money. We try to answer all three honestly here. The headline: Promotes wound healing, cardiac repair, and corneal regeneration in animal models.

What is TB-500?

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in cell migration and angiogenesis. Preclinical work suggests roles in cardiac repair, wound healing, and corneal recovery.

There is no single FDA-licensed manufacturer of TB-500 for human therapeutic use. Material in the research and grey markets is supplied by various unregulated sources, which raises real questions about purity and dosing accuracy. TB-500 is not currently approved by the FDA for general human use. Available evidence comes from animal and cell-culture studies. We do not endorse self-administration of unapproved compounds.

The drug class research peptide (not fda-approved) works by targeting specific receptor pathways. Here's what to expect.

How TB-500 Works in the Body

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in cell migration and angiogenesis. Preclinical work suggests roles in cardiac repair, wound healing, and corneal recovery. The receptor target — compound-specific — drives the downstream effects users care about: promotes wound healing, cardiac repair, and corneal regeneration in animal models.

The pharmacokinetics matter for daily use. TB-500 has a half-life of approximately 2-3 hours after subcutaneous administration in animal studies, which determines how often it is dosed. The standard route of administration is subcutaneous injection (in research), and the typical schedule is weekly loading then maintenance protocols are described in non-clinical literature.

For more detail on the underlying biology, see our breakdown of how TB-500 works.

Who Uses TB-500?

TB-500 is most relevant for people whose situation maps to its approved indications: none for human use.

People who should avoid TB-500 include those with the following:

• allergy to the active ingredient or any excipient
• pregnancy or breastfeeding (per label)
• conditions specifically called out in the prescribing information

Common and Serious Side Effects

The most commonly reported side effects of TB-500 include:

• limited human safety data

Serious risks — uncommon but worth knowing — include:

• unknown long-term effects
• theoretical pro-angiogenic concerns
• supply-chain contamination risk

We have a more detailed breakdown in our TB-500 side-effects guide.

TB-500 vs Alternatives

FDA-approved options for the conditions TB-500 has been studied in (cardiac repair, dry eye, wound healing) include established pharmaceutical and procedural therapies — none of which involve TB-500. If you are weighing TB-500 against another option, our comparison pages include TB-500 Side Effects Decoded: What's Normal vs. What Isn't, What Results Should You Expect from TB-500? A Practical Guide, The Real TB-500 Price Tag in 2026 — With and Without Insurance.

Bottom Line

Treat TB-500 as one tool among several. The most successful users we see treat it as part of a structured approach, not a standalone fix. Evidence remains preliminary; we recommend caution and clinician oversight. If you are considering TB-500, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• TB-500 Side Effects Decoded: What's Normal vs. What Isn't
• What Results Should You Expect from TB-500? A Practical Guide
• The Real TB-500 Price Tag in 2026 — With and Without Insurance
• TB-500 Protocols: A Research-Based Overview (Not a Recommendation)
• What Is BPC-157? Everything You Should Know Before Starting
• Is BPC-157 Safe? An Honest Look at the Side-Effect Profile

Sources

• Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157 — Major Wound-Healing Properties. Pharmaceuticals 2020;13:155.
• Goldstein AL et al. Thymosin β4: A Multi-Functional Regenerative Peptide. Annals NY Acad Sci 2012;1269:1.
• Sosne G et al. Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy. Expert Opinion 2015;15:663.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.